These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 21355309

  • 1. [The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance].
    Xie C, Yin RT, Li YL, Kang DY, Xu L, Yang KX.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):86-9. PubMed ID: 21355309
    [Abstract] [Full Text] [Related]

  • 2. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    Steffensen KD, Smoter M, Waldstrøm M, Grala B, Bodnar L, Stec R, Szczylik C, Jakobsen A.
    Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
    [Abstract] [Full Text] [Related]

  • 3. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.
    Lin K, Ye D, Xie X.
    Int J Gynecol Cancer; 2008 May; 18(5):1007-12. PubMed ID: 18081788
    [Abstract] [Full Text] [Related]

  • 4. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
    Chen L, Liang L, Yan X, Liu N, Gong L, Pan S, Lin F, Zhang Q, Zhao H, Zheng F.
    Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
    [Abstract] [Full Text] [Related]

  • 5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
    Qi BL, Li Y, Wang N, Zhou RM, Hu P, Kang S.
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
    [Abstract] [Full Text] [Related]

  • 6. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD, Waldstrøm M, Jeppesen U, Brandslund I, Jakobsen A.
    Int J Gynecol Cancer; 2008 Nov; 18(4):702-10. PubMed ID: 17961161
    [Abstract] [Full Text] [Related]

  • 7. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
    Zhao D, Zhang W, Li XG, Wang XB, Li M, Li YF, Tian HM, Song PP, Liu J, Chang QY, Wu LY.
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
    [Abstract] [Full Text] [Related]

  • 8. Comparison of ERCC1/XPF genetic variation, mRNA and protein levels in women with advanced stage ovarian cancer treated with intraperitoneal platinum.
    Deloia JA, Bhagwat NR, Darcy KM, Strange M, Tian C, Nuttall K, Krivak TC, Niedernhofer LJ.
    Gynecol Oncol; 2012 Sep; 126(3):448-54. PubMed ID: 22609620
    [Abstract] [Full Text] [Related]

  • 9. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD, Waldstrøm M, Jakobsen A.
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [Abstract] [Full Text] [Related]

  • 10. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
    Moxley KM, Benbrook DM, Queimado L, Zuna RE, Thompson D, McCumber M, Premkumar P, Thavathiru E, Hines L, Moore KN.
    Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
    [Abstract] [Full Text] [Related]

  • 11. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ, Braicu I, Nassir M, Richter R, Sehouli J, Arsenic R.
    Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
    [Abstract] [Full Text] [Related]

  • 12. Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
    Zhang Z, Dou X, Yang H, Jia L, Qin K, Gao X, Yang B, Zhang W, Qin C, Zhang F, Shan B.
    Pathol Res Pract; 2020 Feb; 216(2):152794. PubMed ID: 31902551
    [Abstract] [Full Text] [Related]

  • 13. Expression and clinical implication of Beclin1, HMGB1, p62, survivin, BRCA1 and ERCC1 in epithelial ovarian tumor tissues.
    Ju LL, Zhao CY, Ye KF, Yang H, Zhang J.
    Eur Rev Med Pharmacol Sci; 2016 May; 20(10):1993-2003. PubMed ID: 27249597
    [Abstract] [Full Text] [Related]

  • 14. LDR reverses DDP resistance in ovarian cancer cells by affecting ERCC-1, Bcl-2, Survivin and Caspase-3 expressions.
    Ju X, Yu H, Liang D, Jiang T, Liu Y, Chen L, Dong Q, Liu X.
    Biomed Pharmacother; 2018 Jun; 102():549-554. PubMed ID: 29597088
    [Abstract] [Full Text] [Related]

  • 15. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
    Kucukgoz Gulec U, Gumurdulu D, Guzel AB, Paydas S, Seydaoglu G, Acikalin A, Khatib G, Zeren H, Vardar MA, Altintas A.
    Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
    [Abstract] [Full Text] [Related]

  • 16. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
    Kuhlmann JD, Wimberger P, Bankfalvi A, Keller T, Schöler S, Aktas B, Buderath P, Hauch S, Otterbach F, Kimmig R, Kasimir-Bauer S.
    Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
    [Abstract] [Full Text] [Related]

  • 17. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
    Rubatt JM, Darcy KM, Tian C, Muggia F, Dhir R, Armstrong DK, Bookman MA, Niedernhofer LJ, Deloia J, Birrer M, Krivak TC.
    Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
    [Abstract] [Full Text] [Related]

  • 18. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S, Su D, Rigault de la Longrais IA, Schwartz P, Puopolo M, Rutherford TJ, Mor G, Yu H, Katsaros D.
    J Clin Oncol; 2007 Nov 20; 25(33):5172-9. PubMed ID: 18024864
    [Abstract] [Full Text] [Related]

  • 19. Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    Du J, Li B, Fang Y, Liu Y, Wang Y, Li J, Zhou W, Wang X.
    BMC Cancer; 2015 Jul 23; 15():536. PubMed ID: 26198101
    [Abstract] [Full Text] [Related]

  • 20. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
    Xie D, Yin RT, Li KM, Xiao P, Tong LX.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul 23; 45(4):606-11. PubMed ID: 25286685
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.